Clinical Study to Confirm the Safety and Performance of the Virtuoso Phaco-vitrectomy Device
Key facts
- Who runs it
- Beaver-Visitec International, Inc.
- Where
- Germany1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 205 people, planned
- Started
- 3 Dec 2025
- Expected to end
- Nov 2026
- Type of study
- Observational, 3 groups
- Record updated
- 1 July 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Primary or repeat vitrectomy (only applicable to patients scheduled for vitrectomy or combined procedure)
- Patients aged ≥ 18 years
- Willing and able to provide written informed consent for participation in the study
- Willing and able to comply with scheduled visits and other study procedures
Who cannot take part
- Patients with ocular comorbidities affecting surgical view including corneal opacities or scar
- Participation in (or current participation) any ophthalmic investigational drug or ophthalmic device trial within the previous 30 days prior to the start date of this trial
- History of intraocular inflammation
- Untreated diabetes
- Pre-operative endothelial cell count <1500 cells/cm2 (only applicable to patients considered for the cataract subgroup or the combined surgeries subgroup)
- Patients aged < 18 years
- No post-operative 90 days visit is anticipated
- Patients requiring or having already had scleral buckling
- Advanced and secondary glaucoma
- Microphthalmos or macrophthalmos
- Post-Traumatic eye
- Subluxated lens
- Morganian cataract
- Weak zonules: zonuli lysis or zonula laxa manifest
- Pregnant or nursing females
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a pre-market clinical investigation with a device that does not bear the CE-marking. Aim of the study is to confirm the safety and performance of the device and collect user feedback.
The 3 groups in the trial
- Cataract subgroup
The patients recruited in this subgroup will undergo their routine cataract surgery. The Vitrectomy device will be used during surgery during the phacoemulsification phase of the surgery.
- Pars-plana Vitrectomy subgroup
The patients in this group will undergo the pars-plana vitrectomy surgery prescribed by their eye doctor. The device will be used to remove the vitreous humor and/or scar tissue which affect the retina.
- Combined PPV and Cataract Subgroup
The patients included in this group will undergo combined surgery as recommended by their eye doctor. The device will be used for the phacoemulsification and pars-plana vitrectomy phases of the surgery.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 1 July 2026